Cancerous tumors start small and grow larger over time, adding defensive mechanisms that make them resistant to treatments and more deadly. So, to find cancers at the earlier stages when they can be treated more effectively, clinicians must have the ability to detect smaller tumors. That’s why Imagion Biosystems is working hard to develop MagSense® superparamagnetic relaxometry (SPMR) technology.
The chart below illustrates the theoretical relative limits of detection of SPMR vs conventional imaging methods (CT and MRI):
We believe that MagSense technology could have the ability to accurately detect a roughly spherical tumor of approximately one millimeter diameter. Relative to conventional imaging methods, this could allow diagnosis to occur significantly earlier. And save lives.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer